Qualyst Transporter Solutions acquired by BioIVT in 2017
Qualyst Transporter Solutions, LLC
Qualyst Transporter Solutions, LLC (Qualyst) provided in vitro hepatic models to predict the effect of drugs and other compounds on the human liver. Qualyst’s in vitro models integrated hepatic uptake, metabolism, regulation, and efflux and demonstrated superior in vitro-in vivo correlation compared to conventional systems. Qualyst’s proprietary technology, products, and services are used by leading pharmaceutical, nutrition, cosmetics, and consumer products, and chemical companies to provide clinically-relevant answers to liver-related questions, and to address regulatory concerns about their products.
Through its acquisition in September 2017 of Qualyst, BioIVT further strengthened its portfolio of specialized ADME-Tox research services focused around the liver. In addition, BioIVT gained access to B-CLEAR® Technology and the C-DILI™ Assay, Qualyst’ proprietary technologies to help assess the efficacy and safety of drugs in development.
Read the full release for more details about the Qualyst acquisition.